Brogan, A. J., Davis, A. E., Mellott, C. E., Fraysse, J., Metzner, A. A., & Oglesby, A. K. (2024). Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics, 42(4), 447-461. https://doi.org/10.1007/s40273-023-01342-y
Citácia podle Chicago (17th ed.)Brogan, Anita J., Ashley E. Davis, Claire E. Mellott, Jeremy Fraysse, Aimee A. Metzner, a Alan K. Oglesby. "Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States." PharmacoEconomics 42, no. 4 (2024): 447-461. https://doi.org/10.1007/s40273-023-01342-y.
Citácia podľa MLA (8th ed.)Brogan, Anita J., et al. "Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States." PharmacoEconomics, vol. 42, no. 4, 2024, pp. 447-461, https://doi.org/10.1007/s40273-023-01342-y.